| |||
| Clinical data | |||
|---|---|---|---|
| Trade names | Leritine | ||
| AHFS/Drugs.com | Monograph | ||
| Routes of administration | Tablets, injection | ||
| ATC code | |||
| Legal status | |||
| Legal status | |||
| Pharmacokinetic data | |||
| Protein binding | > 95% | ||
| Metabolism | Hepatic | ||
| Identifiers | |||
| |||
| CAS Number |
| ||
| PubChemCID | |||
| IUPHAR/BPS | |||
| DrugBank |
| ||
| ChemSpider |
| ||
| UNII | |||
| KEGG |
| ||
| ChEBI | |||
| ChEMBL | |||
| CompTox Dashboard(EPA) | |||
| Chemical and physical data | |||
| Formula | C22H28N2O2 | ||
| Molar mass | 352.478 g·mol−1 | ||
| 3D model (JSmol) | |||
| Melting point | 83 °C (181 °F) | ||
| |||
| |||
 N Y (what is this?) (verify) | |||
Anileridine (trade name:Leritine) is a syntheticanalgesic drug[2] and is a member of thepiperidine class of analgesic agents[3] developed by Merck & Co. in the 1950s.[4] It differs frompethidine (meperidine) in that theN-methyl group of meperidine is replaced by anN-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada.[5] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate.[6] It is also under international control per UN treaties.
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[8] It is mostly metabolized by theliver.
